Breast Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Breast Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Breast Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global breast cancer market. The report identifies the key trends shaping and driving the global breast cancer market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global breast cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData’s analysis suggests that the global breast cancer market was worth $8.7 billion in 2009. It is forecast to grow at a compound annual growth rate (CAGR) of 6% for the next eight years, to reach $13.86 billion by 2017. The high projected growth rate is primarily attributable to a strong pipeline. Increases in the treatment seeking population, the diagnosis population, and the availability of new first-in-class therapies with better safety and efficacy are expected to drive the growth of the breast cancer market.

Scope

The report provides information on the key drivers and challenges of the breast cancer market. Its scope includes:

• Annualized global breast cancer market revenues data from 2001 to 2009, forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as GnRH antagonists, GnRH synergists, aromatase inhibitors, antiprogestins and steroid sulfatase inhibitors.
• Analysis of the current and future competition in the global breast cancer market. Key market players covered are Bayer Healtcare Pharmaceuticals, Pfizer Inc, Neurocrine Biosciences Inc., Æterna Zentaris Inc. and Repros Therapeutics Inc.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the breast cancer therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global breast cancer market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global breast cancer market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global breast cancer market landscape? – Identify, understand and capitalize.

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 BREAST CANCER INTRODUCTION

2.1 Overview
2.2 TNM Classification
2.3 Risk Factors
2.4 Signs and Symptoms
2.5 Diagnosis
2.6 GlobalData Pipeline Report Guidance

3 BREAST CANCER MARKET: MARKET CHARACTERIZATION

3.1 Overview
3.2 Breast Cancer Market Size
3.3 Breast Cancer Market Forecast and CAGR
3.4 Drivers and Barriers for the Breast Cancer Market
  3.4.1 Drivers for the Breast Cancer Market
  3.4.2 Barriers for the Breast Cancer Market
3.5 Opportunity and Unmet Need
3.6 Key Takeaway

4 BREAST CANCER THERAPEUTICS: COMPETITIVE ASSESSMENT

4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles of the Major Marketed Products in the Breast Cancer Market
  4.3.1 Abraxane (albumin bound paclitaxel)
  4.3.2 Arimidex (anastrozole)
  4.3.3 Femara (letrozole)
  4.3.4 Herceptin (trastuzumab)
  4.3.5 Taxotere (docetaxel)
  4.3.6 Xeloda (capecitabine)
  4.3.7 Tykerb (Lapatinib)
  4.3.8 Avastin (bevacizumab) + Paclitaxel
4.4 Key Takeaway

5 BREAST CANCER THERAPEUTICS: PIPELINE ASSESSMENT

5.1 Overview
5.2 Strategic Pipeline Assessment
  5.2.1 Technology Trends Analytic Framework
5.3 Molecule Profile for Promising Drugs under Clinical Development
  5.3.1 Halaven (Eribulin)
  5.3.2 Afinitor
  5.3.3 NeuVax
5.4 Breast Cancer Therapeutics Market – Clinical Pipeline by Mechanism of Action
5.5 Breast Cancer Pipeline – Pipeline by Clinical Phases of Development
  5.5.1 Breast Cancer Therapeutics – Phase III Clinical Pipeline
  5.5.2 Breast Cancer Therapeutics – Phase II Clinical Pipeline
  5.5.3 Breast Cancer Therapeutics – Phase I Clinical Pipeline
  5.5.4 Breast Cancer Therapeutics – Preclinical and Discovery Pipeline
5.6 Key Takeaway

6 BREAST CANCER THERAPEUTICS: IMPLICATIONS FOR FUTURE MARKET COMPETITION

7 BREAST CANCER THERAPEUTICS: FUTURE PLAYERS IN THE BREAST CANCER MARKET

7.1 Introduction
7.2 Novartis AG
  7.2.1 Company Overview
  7.2.2 Oncology Portfolio
7.3 GlaxoSmithKline plc (GSK)
  7.3.1 Overview
7.4 F. Hoffmann-La Roche Ltd.
  7.4.1 Overview
  7.4.2 Business Description
7.5 Pfizer Inc.
  7.5.1 Overview
  7.5.2 Business Description
7.6 Eli Lilly and Company
  7.6.1 Overview
  7.6.2 Business Description
7.7 Eisai Co., Ltd.
  7.7.1 Company Overview
  7.7.2 Business Description

8 BREAST CANCER MARKET: APPENDIX

8.1 Market Definition
8.2 Abbreviations
8.3 Research Methodology
  8.3.1 Coverage
  8.3.2 Secondary Research
  8.3.3 Forecasting
  8.3.4 Primary Research
  8.3.5 Expert Panel Validation
8.4 Contact Us
8.5 Disclaimer
8.6 Sources 58

LIST OF TABLES

Table 1: Breast Cancer Stage Classification
Table 2: Breast Cancer Therapeutics, Global, Revenue ($bn), 2001–2009
Table 3: Breast Cancer Therapeutics, Global, Revenue Forecast ($bn), 2009–2017
Table 4: Other 32% Consists of the Following Mechanisms of Action, 2010
Table 5: Breast Cancer Pipeline, Phase III, 2010
Table 6: Breast Cancer Pipeline, Phase II, 2010
Table 7 Breast Cancer Pipeline, Phase I, 2010
Table 8 Breast Cancer Pipeline, Pre-clinical and Discovery Phase, 2010
Table 9: Novartis – Oncology Pipeline, 2010
Table 10: GlaxoSmithKline – Oncology Pipeline, 2010
Table 11: F. Hoffmann-La Roche Ltd – Oncology Pipeline, 2010
Table 12: Pfizer Oncology Pipeline, 2010
Table 13: Eli Lilly and Company – Oncology Pipeline, 2010
Table 14: Eisai – Oncology Pipeline, 2010 51

LIST OF FIGURES

Figure 1: Breast Cancer Therapeutics, Global, Revenue Forecast ($bn), 2009–2017
Figure 2: Breast Cancer Therapeutics, Global, Revenue Forecast ($bn), 2009–2017
Figure 3: Opportunity and Unmet Need in the Breast Cancer Market, 2010
Figure 4: Strategic Competitor Assessment of the Marketed Products for Breast Cancer, 2010
Figure 5: Technology Trends Analytic Framework of the Breast Cancer Pipeline, 2010
Figure 6: Technology Trends Analytic Framework of the Breast Cancer Pipeline – Description, 2010
Figure 7: Breast Cancer Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010
Figure 8: Breast Cancer Pipeline by Phase of Clinical Development, 2010
Figure 9: Implications for Future Market Competition in Breast Cancer Therapeutics, 2010
Figure 10: Breast Cancer Therapeutics Market – Clinical Pipeline by Company, 2010
Figure 11: GlobalData Market Forecasting Model 56

COMPANIES MENTIONED

Skip to top